The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer
Open accessAbstract
Importance: Understanding adverse effects of contemporary treatment approaches for men with favorable-risk and unfavorable-risk localized prostate cancer could inform treatment selection. Objective: To compare functional outcomes associated with prostate cancer treatments over 5 years after treatment. Design, Setting, and Participants: Prospective, population-based cohort study of 1386 men with favorable-risk (clinical stage cT1 to cT2bN0M0, prostate-specific antigen [PSA] ≤20 ng/mL, and Grade Group 1-2) prostate cancer and 619 men with unfavorable-risk (clinical stage cT2cN0M0, PSA of 20-50 ng/mL, or Grade Group 3-5) prostate cancer diagnosed in 2011 through 2012, accrued from 5 Surveillance, Epidemiology and End Results Program sites and a US prostate cancer registry, with surveys through September 2017. Exposures: Treatment with active surveillance (n = 363), nerve-sparing prostatectomy (n = 675), external beam radiation therapy (EBRT; n = 261), or low-dose-rate brachytherapy (n = 87) for men with favorable-risk disease and treatment with prostatectomy (n = 402) or EBRT with androgen deprivation therapy (n = 217) for men with unfavorable-risk disease. Main Outcomes and Measures: Patient-reported function, based on the 26-item Expanded Prostate Index Composite (range, 0-100), 5 years after treatment. Regression models were adjusted for baseline function and patient and tumor characteristics. Minimum clinically important difference was 10 to 12 for sexual function, 6 to 9 for urinary incontinence, 5 to 7 for urinary irritative symptoms, and 4 to 6 for bowel and hormonal function. Results: A total of 2005 men met inclusion criteria and completed the baseline and at least 1 postbaseline survey (median [interquartile range] age, 64 [59-70] years; 1529 of 1993 participants [77%] were non-Hispanic white). For men with favorable-risk prostate cancer, nerve-sparing prostatectomy was associated with worse urinary incontinence at 5 years (adjusted mean difference, -10.9 [95% CI, -14.2 to -7.6]) and sexual function at 3 years (adjusted mean difference, -15.2 [95% CI, -18.8 to -11.5]) compared with active surveillance. Low-dose-rate brachytherapy was associated with worse urinary irritative (adjusted mean difference, -7.0 [95% CI, -10.1 to -3.9]), sexual (adjusted mean difference, -10.1 [95% CI, -14.6 to -5.7]), and bowel (adjusted mean difference, -5.0 [95% CI, -7.6 to -2.4]) function at 1 year compared with active surveillance. EBRT was associated with urinary, sexual, and bowel function changes not clinically different from active surveillance at any time point through 5 years. For men with unfavorable-risk disease, EBRT with ADT was associated with lower hormonal function at 6 months (adjusted mean difference, -5.3 [95% CI, -8.2 to -2.4]) and bowel function at 1 year (adjusted mean difference, -4.1 [95% CI, -6.3 to -1.9]), but better sexual function at 5 years (adjusted mean difference, 12.5 [95% CI, 6.2-18.7]) and incontinence at each time point through 5 years (adjusted mean difference, 23.2 [95% CI, 17.7-28.7]), than prostatectomy. Conclusions and Relevance: In this cohort of men with localized prostate cancer, most functional differences associated with contemporary management options attenuated by 5 years. However, men undergoing prostatectomy reported clinically meaningful worse incontinence through 5 years compared with all other options, and men undergoing prostatectomy for unfavorable-risk disease reported worse sexual function at 5 years compared with men who underwent EBRT with ADT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
A heteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity
White, H. (1980) · Econometrica · doi:10.2307/1912934 · Cited by 25,861
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
Multiple imputation using chained equations: Issues and guidance for practice
White, I. R., Royston, P., & Wood, A. M. (2011) · Statistics in Medicine · doi:10.1002/sim.4067 · Cited by 9,792
MCHORNEY, C. A., JOHNE, W., & ANASTASIAE, R. (1993) · Medical Care · doi:10.1097/00005650-199303000-00006 · Cited by 6,681
Sherbourne, C. D., & Stewart, A. L. (1991) · Social Science & Medicine · doi:10.1016/0277-9536(91)90150-b · Cited by 6,643
Analysis of Incomplete Multivariate Data
Schafer, J. L. (1997) · doi:10.1201/9781439821862 · Cited by 6,012
Proportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885 · cited 5×
“001 48 (12-80) [n = 199] 70 (33-85) [n = 381] 61 (23-85) [n = 580] <.”
InfluentialAnalysis of Incomplete Multivariate Data
Booth, D. E. (2000) · Technometrics · doi:10.1080/00401706.2000.10486013 · Cited by 5,627
Screening for Depression in Well Older Adults: Evaluation of a Short Form of the CES-D
Andresen, E. M., Malmgren, J. A., Carter, W. B., & Patrick, D. L. (1994) · American Journal of Preventive Medicine · doi:10.1016/s0749-3797(18)30622-6 · Cited by 5,403
(1967) · Project Euclid (Cornell University) · Cited by 4,720
Andresen, E. M., Malmgren, J. A., Carter, W. B., & Patrick, D. L. (1994) · PubMed · Cited by 4,426
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer
Hamdy, F. C., Donovan, J. L., Lane, J. A., Mason, M., Metcalfe, C., Holding, P., Davis, M., Peters, T. J., Turner, E. L., Martin, R. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606220 · Cited by 2,640
Quality of Life and Satisfaction with Outcome among Prostate-Cancer Survivors
Sanda, M. G., Dunn, R. L., Michalski, J., Sandler, H. M., Northouse, L., Hembroff, L., Lin, X., Greenfield, T. K., Litwin, M. S., Saigal, C. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074311 · Cited by 2,253
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Mohler, J. L., Antonarakis, E. S., Armstrong, A. J., D’Amico, A. V., Davis, B. J., Dorff, T., Eastham, J. A., Enke, C. A., Farrington, T. A., Higano, C. S., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0023 · Cited by 1,532
Self-citation(2006) · Cancer · doi:10.1002/(issn)1097-0142 · Cited by 1,470
Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer
Donovan, J. L., Hamdy, F. C., Lane, J. A., Mason, M., Metcalfe, C., Walsh, E., Blazeby, J. M., Peters, T. J., Holding, P., Bonnington, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606221 · Cited by 1,338
Sanda, M. G., Cadeddu, J. A., Kirkby, E., Chen, R. C., Crispino, T., Fontanarosa, J., Freedland, S. J., Greene, K. L., Klotz, L. H., Makarov, D. V., et al. (2017) · The Journal of Urology · doi:10.1016/j.juro.2017.11.095 · Cited by 830
Potosky, A. L., Davis, W. W., Hoffman, R. M., Stanford, J. L., Stephenson, R. A., Penson, D. F., & Harlan, L. C. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh259 · Cited by 680
Self-citationCharacteristics of Physicians with Participatory Decision-Making Styles
Kaplan, S. H., Greenfield, S., Gandek, B., Rogers, W. H., & Ware Jr., J. E. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-5-199603010-00007 · Cited by 611
Self-citationSzymanski, K. M., Wei, J. T., Dunn, R. L., & Sanda, M. G. (2010) · Urology · doi:10.1016/j.urology.2010.01.027 · Cited by 456
Racial and Ethnic Differences in Advanced-Stage Prostate Cancer: the Prostate Cancer Outcomes Study
Hoffman, R. M., Gilliland, F. D., Eley, J. W., Harlan, L. C., Stephenson, R. A., Stanford, J. L., Albertson, P. C., Hamilton, A. S., Hunt, W. C., & Potosky, A. L. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.5.388 · Cited by 441
Self-citationBarocas, D. A., Alvarez, J., Resnick, M. J., Koyama, T., Hoffman, K. E., Tyson, M. D., Conwill, R., McCollum, D., Cooperberg, M. R., Goodman, M., et al. (2017) · JAMA · doi:10.1001/jama.2017.1704 · Cited by 344
Self-citationCOOPERBERG, M. R., BROERING, J. M., LITWIN, M. S., LUBECK, D. P., MEHTA, S. S., HENNING, J. M., CARROLL, P. R., & the CaPSURE INVESTIGATORS (2004) · Journal of Urology · doi:10.1097/01.ju.0000107247.81471.06 · Cited by 340
Self-citationMinimally Important Difference for the Expanded Prostate Cancer Index Composite Short Form
Skolarus, T. A., Dunn, R. L., Sanda, M. G., Chang, P., Greenfield, T. K., Litwin, M. S., Wei, J. T., Regan, M., Hembroff, L., Wei, J. T., et al. (2015) · Urology · doi:10.1016/j.urology.2014.08.044 · Cited by 335
Chen, R. C., Basak, R., Meyer, A.-M., Kuo, T.-M., Carpenter, W. R., Agans, R. P., Broughman, J. R., Reeve, B. B., Nielsen, M. E., Usinger, D. S., et al. (2017) · JAMA · doi:10.1001/jama.2017.1652 · Cited by 325
Punnen, S., Cowan, J. E., Chan, J. M., Carroll, P. R., & Cooperberg, M. R. (2015) · European Urology · doi:10.1016/j.eururo.2014.08.074 · Cited by 191
Self-citationTreatment decisions for localized prostate cancer: Asking men what’s important
Holmboe, E. S., & Concato, J. (2000) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2000.90842.x · Cited by 159
Avulova, S., Zhao, Z., Lee, D. J., Huang, L., Koyama, T., Hoffman, K. E., Conwill, R. M., Wu, X., Chen, V. W., Cooperberg, M. R., et al. (2017) · The Journal of Urology · doi:10.1016/j.juro.2017.12.037 · Cited by 103
Self-citationAssessment of prognosis with the total illness burden index for prostate cancer
Litwin, M. S., Greenfield, S., Elkin, E. P., Lubeck, D. P., Broering, J. M., & Kaplan, S. H. (2007) · Cancer · doi:10.1002/cncr.22615 · Cited by 100
Self-citationJayadevappa, R., Malkowicz, S. B., Wittink, M. N., Wein, A. J., & Chhatre, S. (2012) · Health Services Research · doi:10.1111/j.1475-6773.2012.01395.x · Cited by 78
Barocas, D. A., Chen, V. W., Cooperberg, M. R., Goodman, M. G., Graff, J. J., Greenfield, S., Hamilton, A. S., Hoffman, K. E., Kaplan, S. H., Koyama, T., et al. (2013) · Journal of Comparative Effectiveness Research · doi:10.2217/cer.13.34 · Cited by 71
Self-citationJohnson, T. K., Gilliland, F. D., Hoffman, R. M., Deapen, D., Penson, D. F., Stanford, J. L., Albertsen, P. C., & Hamilton, A. S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.127 · Cited by 70
Self-citationZeléfsky, M. J., Poon, B. Y., Eastham, J. A., Vickers, A. J., Pei, X., & Scardino, P. T. (2016) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2015.11.035 · Cited by 59
Lee, D. J., Barocas, D. A., Zhao, Z., Huang, L., Koyama, T., Resnick, M. J., Conwill, R. M., McCollum, D., Cooperberg, M. R., Goodman, M. G., et al. (2018) · Practical Radiation Oncology · doi:10.1016/j.prro.2018.04.009 · Cited by 17
Self-citationO'Neil, B. B., Hoffman, K. E., Koyama, T., Alvarez, J., Conwill, R. M., Albertsen, P. C., Cooperberg, M. R., Goodman, M. G., Greenfield, S., Hamilton, A. S., et al. (2017) · Urology Practice · doi:10.1016/j.urpr.2017.09.008 · Cited by 3
Self-citation
Cited by
Mottet, N., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Cumberbatch, M. G., De Santis, M., Fanti, S., Fossati, N., Gandaglia, G., Gillessen, S., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.09.042 · Cited by 2,802
Raychaudhuri, R., Lin, D. W., & Montgomery, R. B. (2025) · JAMA · doi:10.1001/jama.2025.0228 · Cited by 355
Kishan, A. U., Ma, T. M., Lamb, J. M., Casado, M., Wilhalme, H., Low, D. A., Sheng, K., Sharma, S., Nickols, N. G., Pham, J., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2022.6558 · Cited by 323
Metadata
- Authors
- Hoffman, K. E., Penson, D. F., Zhao, Z., Huang, L.-C., Conwill, R., Laviana, A. A., Joyce, D. D., Luckenbaugh, A. N., Goodman, M., Hamilton, A. S., Wu, X.-C., Paddock, L. E., Stroup, A., Cooperberg, M. R., Hashibe, M., O’Neil, B. B., Kaplan, S. H., Greenfield, S., Koyama, T., & Barocas, D. A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2020-01-14
- Volume
- 323
- Issue
- 2
- Pages
- 149
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2999081098
- Cited by
- 298
- References
- 37
- FWCI
- 22.41
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.